https://www.thebodypro.com/category/lamivudine-epivir-3tc

Lamivudine (3TC, Epivir)

The Latest

pill bottles on page full of data
Conference Coverage

Two-Drug HIV Regimen Works Well Except in People With Low CD4 Count, Study Finds

The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.

M184V Mutation Associated With Increased Risk of Viral Blip but Not Viral Failure With 3TC-Based Dual Therapy Img
CROI (Conference on Retroviruses and Opportunistic Infections)

M184V Mutation Associated With Increased Risk of Viral Blip but Not Viral Failure With 3TC-Based Dual Therapy

A retrospective analysis presented at CROI 2018 looked at risk of viral rebound in people who switched to lamivudine (Epivir, 3TC)-based dual antiretroviral therapy.

Mark Wainberg and the Enduring Importance of 3TC Img
News

Mark Wainberg and the Enduring Importance of 3TC

Paul Sax, M.D., remembers HIV research pioneer Mark Wainberg, Ph.D., as a "thoughtful virologist" who discovered 3TC's efficacy against HIV.

Promo Image
CROI (Conference on Retroviruses and Opportunistic Infections)

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.

Promo Image
IDWeek

HIV Drug Development Pipeline Update, Fall 2014 Edition

HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.

Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy Img
Conference Coverage

Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy

A recent study revealed a surprising result: For the first time ever, an HIV treatment regimen consisting of two drugs was found to work just as well as a three-drug regimen.

Promo Image
News

FDA Says Merck's HIV Drug Gets Generic Threat

The Food and Drug Administration reports it has received applications from drugmakers who wish to produce generic versions of the HIV drugs Isentress (Merck & Co.) and Epivir (GlaxoSmithKline). Isentress was approved for use in adult patients in 2007...

Promo Image

Dose Optimisation: 50 mg Ritonavir-Boosting, 3TC Dosing and Raltegravir Once-Daily

The issue of dose optimisation is important for several reasons, ranging from finding the right dose for an individual patient that achieves the highest probability of therapeutic success with the lowest risk of adverse events, to as a strategy to de...

Promo Image

Emtricitabine and Lamivudine May Be Similar, but Their Resistance Profiles Differ in Important Ways

Two of the most frequently prescribed components of combination therapy for HIV are the cytidine nucleoside reverse transcriptase inhibitors lamivudine (3TC, Epivir) and emtricitabine (FTC, Emtriva). They are nearly identical in atomic structure, alt...

Promo Image

Lamivudine Monotherapy Better Than Treatment Interruption in Rescue Patients With M184V

Once a patient has gone through a multitude of treatment regimens, finding a fully suppressive salvage regimen can be impossible. It has long been hypothesized that instead of a complete therapeutic interruption, if the M184V mutation is maintained t...